Gain but no pain as Nektar reports more positive no-rush, no-crush opioid
This article was originally published in Scrip
Executive Summary
Nektar Therapeutics reported positive Phase I data for its new mu-opioid analgesic molecule that support further development of NKTR-181 as a treatment for chronic pain with a reduced chance of drug addiction.